Clinical Trials for Tuberculosis Prevention, Detection and Treatment

Tuberculosis (TB) is still the world’s deadliest infectious disease—affecting over 10 million people each year. Yet, global progress towards ending TB is slowing at a time when stronger, evidence-based solutions are urgently needed.

Join us for a compelling seminar with Professor Greg Fox, a global leader in TB research and clinical trials, as he shares how cutting-edge evidence is shaping the future of TB prevention, detection, and treatment.

Clinical Trials for Tuberculosis Prevention, Detection and Treatment

• How population-wide screening can significantly reduce TB incidence in high-burden communities
• The potential of levofloxacin as preventive treatment for drug-resistant TB contacts
• New evidence guiding treatment for isoniazid mono-resistant TB
• Translating clinical trial findings into real-world impact through implementation science
• Opportunities to network with global health researchers, practitioners and students

Date:

17 April 2026, Friday

Time:

11.30am – 12.30pm SGT

Venue:

NUS, Tahir Foundation Building, Seminar Room 2, Level 8, 12 Science Drive 2, S(117549)

Abstract:

Tuberculosis (TB) is the leading infectious cause of morbidity and mortality globally, with over 10 million people affected every year. Two-thirds of affected people live in the Asia-Pacific region. Despite global commitments, progress towards ending TB has stalled. Current efforts are not on track to meet the end TB milestones. With a tightening global health fiscal envelope, it is more critical than ever to invest in evidence-based interventions that can prevent, detect, and treat TB effectively.

The seminar will describe how population-wide screening in a high-TB-burden community significantly reduced disease incidence, how levofloxacin shows promise as preventive treatment for contacts of patients with drug-resistant TB, and how new evidence is informing the design of novel treatment regimens for isoniazid mono-resistant TB, the commonest form of drug-resistant TB. The session will discuss ongoing work in translating trial evidence into real-world practice through implementation science. This lecture will also reflect on lessons learned from conducting collaborative clinical trials in the region and highlight how they are shaping clinical guidelines, patient care, and public health policy globally.

Biography:

Professor Greg Fox is Director of the Sydney Southeast Asia Centre, and Director of the NHMRC Centre for Research Excellence in Tuberculosis at the University of Sydney. He has led clinical trials and research relating to infectious diseases and chronic diseases internationally. His research, in combination with guideline development work, have contributed to changes in global TB policies and clinical practice. His research includes multicentre studies into the prevention and detection of tuberculosis and other lung diseases. Professor Fox works clinically as a Respiratory Physician at Sydney’s Royal Prince Alfred Hospital.